Published in Vaccine Weekly, May 23rd, 2007
"We were effectively targeting ‘bad’ T cells that can damage the immune system if their numbers are too high, and ‘good’ T cells that help create an immune response to things like infections and tumors," said John Sampson, M.D., Ph.D., a neurosurgeon at Duke and senior investigator on the study. "We found that this drug was able to stop the bad cells in their tracks by giving the good ones a type of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly